Posted: June 2, 2010 | |
Experts call on EU to act to secure nanomedicine benefits for all |
|
(Nanowerk News) Experts from key EU projects united in Brussels at Nanomedicine in Europe today to deliver a strong message to the European Parliament that concerted and coordinated action is needed to ensure the widespread benefits offered by advances in nanomedicine are not squandered. | |
Hosted by the NanoMed Round Table and STOA, the specially organised seminar made recommendations in all key areas - Applications, Health-Economic Impact, Patient Needs, Regulatory, Ethics and Communication Issues – with a view to enabling EU policy makers to ensure fast translation of R&D results into clinical applications in what has already been identified a major area for strategic investment in the new Framework 7 programme. | |
The call for action is based on the findings of three European Commission funded projects – NanoMed Round Table and EuroNanoBio - and the Nanomedicine European Technology Platform which during 2009 gathered information and advice from more than 100 leading experts from academia, industry, regulatory agencies and patient organisations throughout Europe to build the most comprehensive picture to date of the nanomedicine sector. | |
According to Prof Sir John Beringer, Chair of the Nanomed Round Table, the free exchange and sharing of information and the mutual involvement of the many experts in these and other national and European projects has provided a solid basis for making recommendations for the successful and sustainable competitiveness of nanomedical research and development in Europe and of its healthcare industries. | |
“Nanomedical applications are not just a theoretical possibility – for example, the Round Table has identified forty-five products that are already on the market. However, the field of nanomedicine is still a relatively new one. This means that Europe is at an ideal moment to consider the impacts and consequences of nanomedicine, as well as action required as a result. We believe that action must be taken as soon as possible. By doing too little or too late or nothing, we would significantly risk hindering or even blocking the development of nanomedicine in Europe to the detriment of European research and development, its healthcare industries, and, most importantly, patients - which includes all of us.” | |
The key recommendations are | |
Source: Schwartz Communications |
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.